Renibus Therapeutics Inc’s Post

Dive into the newest research by Müller et al., which provides evidence for the short- and long-term safety and efficacy in of CD19 #CAR T-cell therapy in autoimmune disease, focusing on #SLE patients. Their findings suggest that CD19 #CAR T-cell transfer appeared to be feasible, safe, and efficacious. For a comprehensive understanding of this pivotal study and its impact on lupus management, access our detailed slide deck available now on the Lupus Forum: https://lnkd.in/dqJUNMa4

Exciting new findings from the Phase 3b #SEQUENCE trial by Peyrin-Biroulet et al. reveal that #risankizumab demonstrates superior efficacy in achieving endoscopic remission at Week 48 compared to #ustekinumab, with no new safety risks identified. Stay ahead in the field of #gastroenterology with our comprehensive slide decks that dive deep into these latest insights on Crohn's Disease treatments. Explore the evolving landscape and enhance your knowledge with the #IMIDForum. 🔗https://ow.ly/xv9350Th7hK

Our novel lupus testing, offered in collaboration with Progentec Diagnostics, Inc., arms clinicians with information that has the potential to enhance disease management, prevent organ damage, and improve patient outcomes. https://bit.ly/3SBIX8I

The LIVERAIM project, A Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy, started on 3 March, 2024, and will last until 28 February, 2030. https://lnkd.in/dcuK-C9p The aim of the project is to identify liver disease early and apply personalized therapy. #liveraim #projekt #MEFZg #medicinskifakultet

A recent study used the Infliximab ELISA to explore the link between infliximab concentrations in tissue and plasma, and their impact on disease activity in ulcerative colitis (UC) patients! Key Findings: 🔹 Plasma infliximab levels reflect tissue exposure in patients in remission, but not in those with active disease. 🔹 Higher infliximab concentrations in non-inflamed tissue are associated with improved durability of remission. #research #infliximab #UlcerativeColitis #eaglebio https://buff.ly/3Niv0cE

This #EuropeanRadiology study assessed the performance of CT/MRI #LIRADS among non-cirrhotic steatotic liver disease (SLD) patients, finding that LI-RADS may be an effective tool in assessing focal liver lesions in SLD. (Jennie Cao et al.) 🔗 https://buff.ly/4cXWWO0

Endoscopic liver “palpation” can be performed by indenting the liver surface under endoscopic ultrasound (EUS). Indentation depth is measured with the use of sonographic calipers. ➡️hypothesized that fibrotic livers are more difficult to indent, and that indentation can accurately predict liver fibrosis staging. Or should we just obtain US elastography?

I am attend the CME about Novel Approaches to Alpha-1 Antitrypsin deficiency-related liver disease:A congress update on June 25,2024 In this activity I learned new Approaches&characteristics regard this disease through #medscape

As we mark Rare Disease Day, Avalyn Pharma aims to shine a light on the challenges faced by patients living with rare lung diseases, especially pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), two of the most severe forms of pulmonary fibrosis, are serious conditions characterized by scarring of the lungs, with a median survival rate of only 3-5 years post-diagnosis. Historically, the treatment landscape for pulmonary fibrosis has been limited, with only two oral medications approved, highlighting the urgency for more effective treatments. This Rare Disease Day, please help us raise awareness for these conditions with high unmet need. For more information on our work and how we're aiming to make a tangible difference in the lives of those with pulmonary fibrosis, visit our website and join us in this crucial conversation. #RareDiseaseDay #IPFAwareness #PPFAwareness #PulmonaryFibrosis #InnovationInCare

Radiation therapy followed by intrathecal trastuzumab and pertuzumab for HER2+ breast leptomeningeal disease is safe with initial intracranial control results that appear encouraging. https://ja.ma/4buN2my